2023
DOI: 10.1097/sla.0000000000005818
|View full text |Cite
|
Sign up to set email alerts
|

Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma

Abstract: Objective: To determine the safety and efficacy of adding the anti-PD-L1 antibody durvalumab to induction FOLFOX and preoperative chemotherapy in locally advanced esophageal adenocarcinoma. Background: Neoadjuvant induction FOLFOX followed by positron emission tomography (PET) directed chemoradiation has demonstrated improved survival for esophageal adenocarcinoma. There is clear benefit now for the addition of immune checkpoint inhibitors both in early… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 27 publications
0
1
0
Order By: Relevance
“…In all patients, the primary endpoints were the probability of survival and overall survival. When compared to placebo, durvalumab significantly improved the life expectancy of patients with locally advanced NSCLC [ 79 , 83 ].…”
Section: Introductionmentioning
confidence: 99%
“…In all patients, the primary endpoints were the probability of survival and overall survival. When compared to placebo, durvalumab significantly improved the life expectancy of patients with locally advanced NSCLC [ 79 , 83 ].…”
Section: Introductionmentioning
confidence: 99%